The targeted use of the Hepatitis A (HAV) vaccine in the U.S. since 1995 has led to a dramatic decrease in the number of reported cases of Hepatitis A.
| Test Name and Number | Recommended Use | Limitations | Follow Up |
|---|---|---|---|
| CBC with Platelet Count & Automated Differential 0040003 Method: Automated Cell Count with Flow Cell Differential |
Initial screening for hepatitis |
||
| Hepatitis Panel, Acute with Reflex to HBsAg Confirmation 0020457 Method: Chemiluminescent Immunoassay/Enzyme Immunoassay |
Confirm infectious agent in patient with acute hepatitis Panel includes testing for HAV IgM, HBV core antibody IgM, HBV surface antigen, HCV antibody |
||
| Hepatitis A Virus Antibodies (Total) 0020591 Method: Chemiluminescent Immunoassay |
Document past infection |
Total assay detects both IgG and IgM antibodies but does not differentiate between them |
Patients with HBV or HCV should receive HAV vaccination if anti-HAV negative |
| Hepatitis A Virus Antibody, IgM 0020093 Method: Chemiluminescent Immunoassay |
Confirm HAV when acute exposure suspected |
Ordering this test in isolation for new-onset suspected hepatitis not recommended |